Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [34] - Revenue from AI solutions for Q3 2025 was $0.1 million, with a gross loss of $1.9 million, compared to revenue of $0.4 million and a gross loss of $1.6 million in the comparable period [34] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][16] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [8] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, increasing revenues, and accelerating its path to profitability [5] - The strategy includes reinforcing its position in the medical AI sector and deepening its foothold in the U.S. healthcare system [5] - The acquisition of VasoHealthcare IT is intended to enhance the company's AI infrastructure and customer service capabilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [6][38] - The company anticipates reaching EBITDA break-even on a quarterly basis in 2026 for the AI business segment and in 2027 for the overall company [30][44] Other Important Information - The company is preparing to launch its next-generation Nano-X ARC X system at the RSNA annual meeting, which is expected to enhance market penetration [9] - The company is actively engaged in clinical trials to validate the effectiveness of its imaging solutions, particularly in lung cancer detection [20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The revenue was generated from a combination of scans and OEM services, with several systems being installed and awaiting regulatory approvals [40] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The majority of agreements are expected to be MSES, with some CapEx sales anticipated [40] Question: Could you talk about how OpEx could look over the next four to six quarters? - Investment in deployment efforts, particularly sales and marketing expenses, is expected to increase, while R&D expenses may be tamed [42] Question: Could you talk about Vaso and the types of customers they currently have? - Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities for Nano-X [42] Question: Could you reiterate the break-even expectations for 2026 and 2027? - The AI business is expected to achieve quarterly break-even in 2026, while the ARC hardware business aims for break-even in 2027 [44][46]